07.01.2015 • News

J&J Buys License Option for Isis Pharma Bowel Drug

US over-the-counter drugmaker Johnson & Johnson will pay Isis Pharmaceuticals up to $835 million for the option to license three drugs targeting autoimmune diseases in the bowel.

Isis Pharmaceuticals said it will receive $35 million in an upfront payment and will be eligible to receive royalties on sales of the drugs.

Janssen Biotech, a unit of Johnson & Johnson, will have the right to license a drug from each of the programs once a candidate is identified, the Carlsbad, California-based developer said.

Interview

Driving Sustainability Through Collaboration
Building Green Practices Across the Chemical Supply Chain

Driving Sustainability Through Collaboration

Together for Sustainability (TfS) is a pioneering, member-led initiative working to accelerate sustainable and resilient chemical supply chains. TfS President Jennifer Jewson discusses the origins of TfS, its evolving goals, its present-day challenges, and the initiative’s enduring impact and outlook for the future.

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

Top-Feature

most read